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Abstract
Background: The larvae of Musca domestica (Diptera: Muscidae) have been used traditionally for malnutritional
stagnation, decubital necrosis, osteomyelitis, ecthyma and lip scald and also to treat coma and gastric cancer in the
traditional Chinese medicine. Its immunomodulatory effects in naïve mice in relation to the traditional uses were also
reported. However, the immunological adjuvant potentials of this insect have not yet been studied.
Methods: The peptide fraction from the larvae of Musca domestica L. (MDPF) was evaluated for its adjuvant potentials
on the immune responses to ovalbumin (OVA) and avian influenza vaccine (rL–H5) by determining antigen-specific
antibody titers, splenocyte proliferation, activity of natural killer (NK) cell, the secretion of cytokines from splenocytes in
the immunized mice.
Results: MDPF significantly enhanced not only the concanavalin A (Con A)-, lipopolysaccharide (LPS)- and
antigen-stimulated splenocyte proliferation, but serum antigen-specific IgG, IgG1, IgG2a, and IgG2b antibody
titers in the mice immunized with OVA and rL–H5. MDPF also remarkably promoted the killing activities of NK
cells in splenocytes from the mice immunized with rL–H5. Furthermore, MDPF significantly promoted the
production of Th1 (IL-2 and IFN-γ) and Th2 (IL-10) cytokines from splenocytes in the immunized mice.
Conclusions: The results indicated that MDPF had a potential to increase both cellular and humoral immune
responses and elicit a balanced Th1/Th2 response, and that MDPF may be a safe and efficacious vaccine adjuvant
candidate.
Keywords: Musca domestica larvae, Peptide, Adjuvant, Avian influenza vaccine, Cellular and humoral, Th1/Th2 immune
responses
Background
Insects and insect derivatives have been widely used in
folk medicine across the world since ancient times [1, 2].
At present, there are approximately 300 medicinal in-
sects distributed in 70 genera, 63 families, and 14 orders.
An estimated 1700 traditional Chinese medicine pre-
scriptions include medicinal insects or insect-derived
crude drugs [3].
Musca domestica (housefly) belongs to the order of Dip-
tera. The larvae of M. domestica have been clinically used
to treat malnutritional stagnation, decubital necrosis, osteo-
myelitis, ecthyma, and lip scald in traditional Chinese medi-
cine [4]. The main constituents of M. domestica larvae
include protein, antimicrobial peptides, polyunsaturated
fats, polysaccharides, lysozyme, agglutinin, vitamins, and
minerals [5]. Among them, antimicrobial peptides such as
cecropin, defensin attacin, and MDpep9 have been paid an
extensive attention [6–8]. Antimicrobial peptides of M.
domestica larvae have been shown to possess the antioxi-
dant [9], antitumor [10, 11], anti-inflammatory [12], anti-
atherosclerosis [13], hepatoprotective [14], antiviral and
immunomodulatory [15] activities.
It was reported that the protein-enriched fraction of
Musca domestica larvae could promote the phagocytic
function of macrophages, 2,4-dinitrofluorobenzene-induced
delayed type hypersensitivity reaction, proliferation of lym-
phocytes, and natural killer cell activity in naïve mice [15].
In our previou works, the peptide fraction from Musca* Correspondence: sunhx@zju.edu.cn
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domestica larvae (MDPF) was found to improve both
specific and non-specific cellular and humoral immune re-
sponse in tumor-bearing mice, and its antitumor activity
might be achieved by switching-on of Th1-based protective
cell-mediated immunity [16]. It was recently reported that
some antimicrobial host defence peptides from insects had
shown excellent vaccine adjuvant properties in mouse
models [17]. Although many adjuvants have been proposed
over the last few decades, the vast majority have not been
successful in being approved for human use, with limita-
tions including unacceptable local or systemic toxicity,
manufacturing difficulties, instability, and prohibitive cost
[18, 19]. To further the search for a novel, safer, and effica-
cious adjuvant, therefore, the current study was undertaken
to evaluate the adjuvant potential of MDPF on the cellular
and humoral immune responses to ovalbumin (OVA) and
Newcastle disease virus-based recombinant avian influenza
vaccine (rL–H5) in mice.
Methods
Materials
Newcastle disease virus-based recombinant influenza
vaccine (rL–H5) and H5 subtype avian influenza virus
antigen (H5–Ag) were purchased from Harbin Weike
Biotechnology Development Company, Heilongjiang,
China. OVA, concanavalin A (Con A), lipopolysacchar-
ide (LPS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT), RPMI-1640 medium, and rabbit
anti-mouse IgG peroxidase conjugate were purchased
from Sigma Chemical Co., Saint Louis, MO, USA; goat
anti-mouse IgG1, IgG2a, and IgG2b peroxidase conju-
gate were from Southern Biotech. Assoc., Birmingham,
AL, USA; cytokine (IL-2, IL-10, and IFN-γ) detecting
ELISA kits were from Wuhan Boster Biological Technol-
ogy Co. Ltd., Hubei, China. Quil A was kindly provided
by Brenntag Nordic A/S, Denmark. Fetal calf serum
(FCS) was purchased from Hyclone, Utah, USA.
Human leukemia K562 cells, sensitive to natural killer
(NK) cells, were purchased from Institute of Cell Biology,
Chinese Academy Sciences. They were maintained in the
logarithmic phase of growth in RPMI-1640 medium sup-
plemented with 2 mM L-glutamine, 100 IU/ml penicillin,
100 μg/ml streptomycin, and 10 % FCS at 37 °C under
humidified air with 5 % CO2.
Preparation and characterization of MDPF
The third instar larvae of Musca domestica were collected
in Zhejiang Xiangshan Nursery, China in November, 2010.
A voucher specimen (No. 20101105) has been deposited
at the Laboratory of Nature Drug, College of Animal
Sciences, Zhejiang University, China, and identified by
professor Jun-An Ye at College of Animal Sciences,
Zhejiang University. MDPF were prepared from the third
instar larvae of Musca domestica and characterized as
previously described [16] (Additional file 1). The protein
content of MDPF was about 56.24 % ± 3.9 % using bovine
serum albumin as the standard. The results of SDS-PAGE
showed that the molecular weights of MDPF were ca. 10
kD (Additional file 1: Figure S1). A stock MDPF solution
with a concentration of 10 mg/ml was prepared by
dissolving in 0.89 % saline. The solution was sterilized by
passing it through a 0.22-μm Millipore filter, and then
analyzed for endotoxin level by a gel-clot Limulus amebo-
cyte lysate assay.
Experimental animals
Female ICR mice (Grade II, 5 weeks old) weighing 18–22 g
were purchased from Zhejiang Experimental Animal Cen-
ter (Certificate No. SCXK 2008‐0033, Hangzhou, China),
and acclimatized for 1 week prior to use. Rodent laboratory
chow and tap water were provided ad libitum and main-
tained under controlled conditions with a temperature of
24 ± 1 °C, humidity of 50 ± 10 %, and a 12/12-h light/dark
cycle. All the procedures were in strict accordance with the
PR China legislation on the use and care of laboratory
animals and with the guidelines established by Institute for
Experimental Animals of Zhejiang University and were
approved by the University Committee for Animal
Experiments.
Toxicity assays
Six-week-old female ICR mice were divided into groups,
each consisting of five mice. Animals were injected twice
subcutaneously (s.c.) on the back with MDPF at a single
dose of 0.5, 1.0, 2.5, and 5.0 mg in 0.5 ml saline solution
at weekly intervals, and monitored daily for 14 days. The
toxicities of Quil A were also determined with one prep-
aration in this study. Varying doses (100, 150, 200 μg) of
Quil A dissolved in saline were injected s.c. in mice.
Saline-treated animals were included as control group.
The toxicity was assessed by lethality, local swelling and
loss of hair at the site of injection.
Immunization
To investigate the adjuvant potentials on the immune
responses to OVA, ICR mice were randomly divided into
six groups, each consisting of six mice. Animals were
subcutaneously (s.c.) injected twice with OVA 25 μg
alone or with OVA 25 μg dissolved in saline containing
Quil A (10 μg) or MDPF (10, 25, or 50 μg) at 2-week
intervals. Saline-treated animals were included as con-
trols. Sera and splenocytes were collected 14 days after
the boosting immunization for measurement of OVA-
specific antibody titers, splenocyte proliferation, and
cytokine levels.
To evaluate the adjuvant effects of MDPF on rL–H5
vaccine, mice were randomly divided into six groups,
with eight mice per group. Animals were immunized s.c.
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twice with rL–H5 (106 EID50/dose) alone or in combin-
ation with Quil A (10 μg), or MDPF (100, 200, or 300 μg)
in 0.2 ml saline on day 1. A boosting injection was given 2
weeks later. Saline-treated animals were included as con-
trols. Sera and splenocytes were collected 2 weeks after
the second immunization for measurement of antigen-
specific antibody titers, splenocyte proliferation, NK cell
activity and cytokine levels.
Splenocyte proliferation assay
Splenocytes were prepared 2 weeks after the secondary
immunization, and cultured with Con A (final concentra-
tion 5 μg/ml), LPS (final concentration 10 μg/ml), OVA
(final concentration 20 μg/ml), H5–Ag (final concentra-
tion 0.125 hemagglutinating units (HAU)/ml), or RPMI-
1640 medium at 37 °C in a humid atmosphere with 5 %
CO2 for 48 h. Splenocyte proliferation was measured by
the MTT method as previously described [20]. The stimu-
lation index (SI) was calculated based on the following
formula: SI = the absorbance value for mitogen-cultures
divided by the absorbance value for non-stimulated
cultures.
Assay of NK cell activity
Splenocytes were prepared as effector cells 2 weeks after
the boosting immunization. The activity of NK cells in
splenocytes was measured by the MTT assay using human
leukemia K562 cell lines as target cells as previously xde-
scribed [21]. Three kinds of control measurements were
performed: target cells control, blank control and effector
cells control. NK cell activity was calculated as following
equation: NK activity (%) = (ODT − (ODS −ODE))/ODT ×
100, where ODT, absorbance of target cells control, ODS,
absorbance of test samples and ODE, absorbance of ef-
fector cells control.
Measurement of serum antigen-specific IgG antibody and
its isotype titers
OVA- or H5–Ag-specific IgG, IgG1, IgG2a, and IgG2b
antibodies in sera were detected in individual serum sam-
ple by an indirect ELISA as previously described [22]. The
absorbance was measured in an ELISA reader at 492 nm,
where sets of sera samples have been subjected to within
and between group comparisons. ELISA assays were per-
formed on the same day for all of the samples.
Cytokine measurements
Splenocytes (5 × 106 cells/well) from the immunized mice
prepared as described above were incubated with Con A
(final concentration 5 μg/ml) in 24-well culture plates at
37 °C in 5% CO2. After 48 h, the plate was centrifuged at
1400 × g for 5 min and culture supernatants were col-
lected for the detection of IL-2, IL-10, and IFN-γ levels
using commercial ELISA kits [20]. The concentrations of
IL-2, IL-10, and IFN-γ were calculated according to the
standard curve using each of the recombinant cytokines
in the ELISA kits.
Statistical analysis
The data were expressed as mean ± standard deviation
(SD) and examined for their statistical significance of dif-
ference with ANOVA and a Tukey post hoc test. P-values




The endotoxin level in a stock MDPF solution with a
concentration of 10 mg/ml was measured to be less than
0.5 endotoxin units (EU)/ml. Therefore, the MDPF
sample used in this study was excluded from endotoxin
contamination. When the animals were administered s.c.
twice at the dose up to 5.0 mg at weekly intervals, there
is no lethality observed. Local swelling or loss of hair
was not observed in mice at the tested doses. In
addition, no MDPF-spcific antibody was detected in the
sera from all the immunized mice in this study. The re-
sults suggested that the safety dose of MDPF used for
mice was at least up to 200 mg/kg. However, the local
swelling and loss of hair were found at the site of injec-
tion in the mice received Quil A at three doses. Further-
more, the numbers of deaths per group of five mice
were 2 and 3 within 72 h after subcutaneous injection of
Quil A at the doses of 150 and 200 μg with one
preparation.
Effect of MDPF on splenocyte proliferation
The effects of MDPF on mitogen-stimulated splenocyte
proliferation in the mice immunized OVA were shown
in Fig. 1a. Con A- and LPS-stimulated splenocyte prolif-
eration in the mice immunized with OVA/Quil A and
OVA/MDPF (10, 25, and 50 μg) was significantly higher
than that in the OVA alone group (P < 0.05, P < 0.01 or
P < 0.001). As shown in Fig. 1b, Quil A and MDPF (100,
200, and 300 μg) also significantly promoted Con A- and
LPS-stimulated splenocyte proliferation in the mice im-
munized with rL–H5 (P < 0.01 or P < 0.001). H5–Ag-in-
duced splenocyte proliferation in mice immunized with
rL-H5/Quil A and rL–H5/MDPF (100, 200, and 300 μg)
was also greater than that observed for the mice immu-
nized with rL–H5 alone (P < 0.01 or P < 0.001).
Effects of MDPF on NK cell activity
The effects of MDPF on NK cell activity in mice immu-
nized with rL–H5 were shown in Fig. 2. Quil A and
MDPF significantly increased the killing percentage of
NK cells in splenocytes from the rL–H5-immunized
mice against K562 cells compared with rL-H5 vaccine
Chen et al. BMC Complementary and Alternative Medicine  (2015) 15:427 Page 3 of 9
alone group (P < 0.05, P < 0.01, or P < 0.001), indicating
that MDPF could promote NK cell lytic activities in the
mice immunized with rL–H5.
Effect of MDPF on the serum antigen-specific antibody
response
The effect of MDPF on the serum OVA-specific IgG and
its isotype titers in the immunized mice were shown in
Fig. 3a. Quil A and MDPF (10, 25, and 50 μg) significantly
increased the OVA-specific serum IgG and IgG1 titers in
OVA-immunized mice (P < 0.05, P < 0.01, or P < 0.001).
Significant enhancements in OVA-specific serum IgG2a
and IgG2b antibody titers were also observed in the mice
immunized with OVA/Quil A and OVA/MDPF compared
with OVA alone group (P < 0.01 or P < 0.001). Similarly, the
serum H5–Ag-specific IgG, IgG1, IgG2a, and IgG2b
antibody titers in rL–H5-immunized mice were also mark-
ably enhanced by Quil A and MDPF (P < 0.05, P < 0.01 or
Fig. 1 Effect of MDPF on mitogen- and antigen-stimulated splenocyte proliferation in the mice immunized with OVA a and rL–H5 b. Splenocyte
proliferation was measured by the MTT method and shown as a stimulation index (SI). The values are presented as means ± SD (n = 6 or 8). Significant
differences with OVA alone or rL–H5 alone group were designated as aP < 0.05, bP < 0.01, and cP < 0.001
Fig. 2 Effect of MDPF on NK cell activity in the splenocytes from the
mice immunized with rL–H5. Splenocytes were prepared 2 weeks
after the secondary immunization, and assayed for NK cell activity by
the MTT assay. The values are presented as means ± SD (n = 8).
Significant differences with rL–H5 alone group were designated as
aP < 0.05, bP < 0.01, or cP < 0.001
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P < 0.001) (Fig. 3b). The findings indicated that MDPF sig-
nificantly promted the humoral immune responses in
OVA- and rL–H5-immunized mice.
Effect of MDPF on cytokine secretion by splenocytes
The calibration curves of IL-2, IFN-γ, and IL-10 were con-
structed with mouse cytokine standards, and their correl-
ation coefficients were all bigger than 0.9980. As shown in
Fig. 4a, the contents of cytokines IL-2, IFN-γ, and IL-10 in
the supernatants from cultured splenocytes in the mice
immunized with OVA/Quil A and OVA/MDPF were sig-
nificantly higher than those in the mice immunized with
in OVA alone (P < 0.05 or P < 0.001). Quil A and MDPF
also significantly promoted the secretion of cytokines
IL-2, IFN-γ, and IL-10 from the splenocytes in the mice
immunized with rL–H5 (P < 0.01 or P < 0.001) (Fig. 4b).
Discussion
Vaccines are one of the most successful medical interven-
tions for the prevention of infectious diseases. New vaccine
technology has led to vaccines containing highly purified
antigens with improved tolerability and safety profiles, but
the immune response they induce is suboptimal without
the help of adjuvants [23]. The use of novel adjuvants in
combination with the immunogen holds great promise
towards the goal of enhancing the potency, breadth and
durability of vaccines [24]. The strong adjuvant activity is
often correlated with increased toxicity. Among nature
products, saponins-based adjuvants, especially Quil A from
the bark of Quillaja saponaria, have been tested widely in
novel vaccine design [25]. The unique capacity of Quil A to
stimulate both the Th1 immune response and the produc-
tion of cytotoxic T-lymphocytes against exogenous antigens
makes it ideal for use in subunit vaccines and vaccines
directed against intracellular pathogens as well as for thera-
peutic cancer vaccines [26]. However, in addition to pain
on injection, severe local reactions and granulomas, tox-
icity includes severe haemolysis [27] making Quil A un-
suitable for human uses other than for life threatening
diseases, such as HIV infection or cancer [28]. In addition,
Fig. 3 Effect of MDPF on antigen-specific IgG and its isotype titers in the mice immunized with OVA a and rL–H5 b. Antigen-specific IgG, IgG1,
IgG2a, and IgG2b antibodies in the sera were measured by an indirect ELISA. The values are presented as means ± SD (n = 6 or 8). Significant
differences with OVA alone or rL–H5 alone group were designated as aP < 0.05, bP < 0.01, and cP < 0.001
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the saponins have a strong adjuvant activity when admin-
istered parenterally, in general, while they have a low or
no activity when delivered orally [29]. The development of
a safe, novel and potent adjuvant with the ability to en-
hance and direct broad and durable immune responses to
these otherwise poorly immunogenic antigens is hence a
top priority [30, 31].
It was reported that the oral maximum tolerated dose
of Musca domestica larvae extracts (MDLE), consisted
of protein fraction and chitosan at the ratio of 10–1, was
more than 33.0 g/kg body weight for mice [32, 33]. The
systemic evaluation of the subchronic toxicity in Sprague
Dawley rats indicated that no observed adverse effect
level for MDLE is 13.2 and 33.0 g/kg bw/day following a
13-week repeated dose in male and female rats, respect-
ively [34]. MDPF used in this study was not found to
cause any side effects, toxicity, and mortality in the mice
injected s.c. twice at the dose up to 5.0 mg at weekly
intervals. In this study, however, Quil A was found to
exhibited severe side effects, toxicity, and lethalities. The
lethalities of mice were 40 % and 60 % within 72 h after
subcutaneous injection of Quil A at the doses of 150
and 200 μg with one preparation, respectively. Kensil et al.
[35] reported that the Quil A was lethal to CD-1 mice in
the dose range of 100–125 μg. The results are consistent
with our findings about Quil A.
Meanwhile, no MDPF-spcific antibody was also de-
tected in all the mice in this study. These results sug-
gested that the MDPF is much safer in clinical use for
human and animals. In addition, antimicrobial peptides
could exert the similar pharmacological effects when
administered parenterally and orally. In our previous
work, the oral administration of MDPF could signifi-
cantly not only enhance splenocytes proliferation, NK
Fig. 4 Effects of MDPF on cytokine production from splenocytes in the mice immunized with OVA a and rL–H5 b. Splenocytes were incubated with
Con A for 48 h, and the culture supernatants were collected for the detection of IL-2, IL-10, and IFN-γ levels using commercial ELISA kits. The values are
presented as means ± SD (n = 6 or 8). Significant differences with OVA alone or rL–H5 alone group were designated as aP < 0.05, bP < 0.01,
and cP < 0.001
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cell and CTL activity, but also promote the production
of IFN-γ and up-regulate the mRNA expression levels of
IFN-γ and Th1 transcription factors T-bet and STAT-4
in splenocytes from the S180-bearing mice [16]. To fur-
ther search a safe, novel and potent adjuvant, in this
study, MDPF was evaluated for the adjuvant potential
on the immune responses to OVA and rL–H5 in mice.
The cellular immune response plays an important role
in the generation of both humoral and cell-mediated
responses to vaccination. The mobilized T lymphocytes
proliferate to protect the body by activating other immune
cells or by killing infected cells. Among the immune cells
activated by T cells, most importantly, are the B lympho-
cytes that produce antibodies. T lymphocytes direct the
types of antibodies that B cells produce and the activity of
other immune cells, thereby directing the immune re-
sponse to optimally provide protection against different
types of infections [36]. The capacity to elicit an effective
T- and B-lymphocyte immunity can be shown by the
stimulation of lymphocyte proliferation response [37]. It is
generally known that Con A stimulates T cell proliferation
and LPS stimulates B cell proliferation. The proliferation
assay showed that MDPF could significantly promote the
Con A-, LPS-, and H5–Ag-stimulated splenocyte prolifer-
ation in the immunized mice (Fig. 1). These results indi-
cated that MDPF was effective in inducing strong
activation potential of T and B cells in OVA- and rL–
H5-immunized mice, and that MDPF showed adjuvant
potentials on the cell-mediated immunity induced by
non-specific or antigen-specific stimulation.
NK cells represent a major population of cytotoxic lym-
phocytes, and are important in the defense against tumors
and viruses [38]. With spontaneous cell-mediated cytotox-
icities, NK cells are functionally similar to CTLs. NK cells
are able to deliver a response immediately after recogniz-
ing specific signals, including stress signals, ‘danger’ signals
or signals from molecules of foreign origin [39]. In this in-
vestigation, MDPF significantly enhanced the lytic activity
of NK cells in mice immunized with rL–H5 (Fig. 2), sug-
gesting that the usage of MDPF in rL–H5 could help to
improve cytolytic activities against avian influenza virus.
Humoral immunity functions by neutralizing and elimin-
ating extracellular microbes and microbial toxins. In
addition to neutralizing properties, antibodies can mediate
host effector functions and facilitate the removal of a patho-
gen from a host. Therefore, the adjuvant activity of MDPF
on serum antigen specific IgG and its isotype antibody re-
sponses to OVA and rL–H5 were also evaluated. In this
study, MDPF significantly not only enhanced OVA- and
H5–Ag-specific IgG and IgG1 titers, but increased specific
IgG2a and IgG2b antibody titers in immunized mice (Fig. 3).
These results clearly demonstrated that MDPF modulated
the quality of immune responses, and elicited a balanced
Th1/Th2 immune response to OVA and rL–H5 in mice as
associated sensitively with an enhancement of IgG2a, IgG2b
and IgG1 levels [40].
Evidence now exists to clearly suggest that Th1 or Th2
responses, generated upon antigenic stimulation, can be
modulated in vivo depending on the adjuvant used for
immunization [41]. The different Th1 and Th2 immune
response profiles correspond to the activation of two
distinct major subsets of T-cells characterized by their
pattern of cytokine production [42]. The Th1 immune
response is characterized by the production of cytokines
IL-2, TNF-β and IFN-γ, and an enhanced production of
IgG2a, IgG2b and IgG3 in mice. The Th2 response is
characterized by the production of cytokines IL-4, IL-5
and IL-10, and an enhanced production of IgG1 and sec-
retary IgA [43]. Immunity to different infectious agents
requires distinct types of immune responses. The Th1
response, correlated with the induction of cell-mediated
immunity [44], is required for protective immunity
against intracellular infectious agents, such as viruses,
certain bacteria and protozoa, and presumably against
cancer cells [45]. Th2 immunity, which controls the
humoral immune response through the triggering of B
cell proliferation and differentiation [46], is effective for
protection against most bacterial as well as certain viral
infections [47]. In order to clearly establish that Th cell-
derived cytokines were involved in the adjuvant activity
of MDPF, we further analyzed the Th1/Th2 cytokine se-
cretion profiles from splenocyte in the mice immunized
OVA and rL–H5 vaccine using ELISA. MDPF not only
significantly increased the production of Th2 cytokines
IL-10, but also strongly enhanced the production of Th1
cytokines IL-2 and IFN-γ from splenocytes in the immu-
nized mice (Fig. 4). These results further confirmed that
MDPF would simultaneously improve Th1 and Th2-type
responses to OVA and rL–H5 in mice.
Host defence peptides (HDPs) exhibit a wide range of
functions ranging from direct antimicrobial properties to
immunomodulatory effects. HDPs are critical effectors of
both innate and adaptive immunity [48]. A range of anti-
microbial HDPs, including defensins and LL-37, might be
effective adjuvants as a result of their ability to modulate
DC function and antigen-specific immune responses [49],
and to elicit the recruitment, differentiation and activation
of effector cells at the site of infection [50]. Whether
MDPF exert the adjuvant action by affecting the local im-
mune microenvironment at the site of injection is being
explored.
The structures of HDPs can be broadly classified as
amphipathic α-helix, β-sheet structures with disulphide
bonds, extended structures, and loop structures with one
disulphide bond [48]. The antimicrobial peptides in M.
domestica were previously reported to be mostly strong al-
kaline [8, 51–54]. However, some weak acidic antibacterial
peptides were also isolated from M. domestica larvae
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[55, 56], suggesting the complicate nature of antibacterial
peptides in Musca domestica larvae. Our studies will be
continuing isolation, purification and characterization of
the antibacterial peptides in MDPF, and clarification of the
relationship between thir adjuvant activity and structure.
In conclusion, the present study demonstrated that
MDPF had immunological adjuvant activity on specific
cellular and humoral immune responses to OVA and
rL–H5 in mice and could simultaneously elicit a Th1
and Th2 immune response. In light of its low or non-
existent toxicity to humans and animals, and long-
standing use as folk medicines, MDPF may be a safe and
efficacious adjuvant candidate suitable for vaccines for
which a balanced and potent stimulation of both the cel-
lular and humoral responses is required. The finding
could provide a reference for the further development of
Musca domestica larvae.
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